<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Potassium citrate and citric acid (powder or solution): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Potassium citrate and citric acid (powder or solution): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Potassium citrate and citric acid (powder or solution): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11409" href="/d/html/11409.html" rel="external">see "Potassium citrate and citric acid (powder or solution): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="16457" href="/d/html/16457.html" rel="external">see "Potassium citrate and citric acid (powder or solution): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F212994"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cytra-K</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F213006"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Alkalinizing Agent, Oral</li></ul></div>
<div class="block doa drugH1Div" id="F212996"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> 1 mL oral solution contains 2 mEq of potassium and the equivalent of 2 mEq of bicarbonate; 1 packet of crystals (powder for oral solution) contains 30 mEq of potassium and the equivalent of 30 mEq of bicarbonate. Individualize dose based on disease state and patient response.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ae31cac7-7452-46d7-b71b-8bdd5844202c">Gout</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gout (adjuvant):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Powder: <b>Oral:</b> One packet dissolved in cool water or juice 4 times daily; adjust dose to urinary pH.</p>
<p style="text-indent:-2em;margin-left:4em;">Solution: <b>Oral: </b>10 to 30 mL 4 times daily; adjust dose based on urinary pH.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f45e942-2de1-4433-a269-dbe8a637db6e">Renal tubular acidosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal tubular acidosis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Powder: <b>Oral: </b>One packet dissolved in cool water or juice 4 times daily; adjust dose based on response.</p>
<p style="text-indent:-2em;margin-left:4em;">Solution: <b>Oral: </b>10 to 30 mL 4 times daily; adjust dose based on response.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ef20dd18-174b-4b79-9e20-64dc963f53b7">Urine alkalinizer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urine alkalinizer:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Powder: <b>Oral: </b>One packet dissolved in cool water or juice 4 times daily; adjust dose to urinary pH.</p>
<p style="text-indent:-2em;margin-left:4em;">Solution: <b>Oral: </b>10 to 30 mL 4 times daily; adjust dose based on urinary pH.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992078"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling. Use is contraindicated in patients with anuria or severe renal impairment with oliguria or azotemia.</p></div>
<div class="block doha drugH1Div" id="F50989273"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F212997"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F213004"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="16457" href="/d/html/16457.html" rel="external">see "Potassium citrate and citric acid (powder or solution): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing presented as mEq bicarbonate and may be presented per dose or per <b>day</b>. Concentration or strength of product formulations may vary. Use caution. For US products, oral solution contains 2 mEq of potassium and the equivalent of 2 mEq of bicarbonate per 1 mL; crystals (powder for oral solution) contain 30 mEq of potassium and the equivalent of 30 mEq of bicarbonate per packet. Individualize dose based on disease state and patient response.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b0d535d6-9c48-4519-8265-12e5bd424209">Ketogenic diet; adjunct therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ketogenic diet; adjunct therapy:</b> Limited data available (Kossoff 2018): Children and Adolescents: Oral: 1 mEq bicarbonate/kg/dose twice daily; potassium citrate/citric acid has been shown to decrease the incidence of nephrolithiasis based on trial experience in 313 patients (McNally 2009); a smaller trial in 22 subjects reported potassium citrate prevented metabolic acidosis without loss of ketogenic diet efficacy (Bjurulf 2020).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7f70e0e3-ed7f-4078-8077-0fe57057abf3">Renal tubular acidosis, distal; type 1</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal tubular acidosis (RTA), distal; type 1: </b>Limited data available: <b>Note:</b> Adjust doses to achieve target bicarbonate levels.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Required doses are highly individualized and will decrease over time as growth rates change; monitor frequently. Doses may need to be divided more frequently than presented (eg, every feed) for tolerability and sustained metabolic control (ERKNet/ESPN [Trepiccione 2021]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Normal serum bicarbonate (identified via screening):</i> Oral: Initial: 1 to 2 mEq/kg/<b>day</b> in at least 4 divided doses (ERKNet/ESPN [Trepiccione 2021]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Low serum bicarbonate: </i>Oral: Initial: 3 to 5 mEq bicarbonate/kg/<b>day</b> in at least 4 divided doses; initiate therapy on the higher end of the range in patients with marked acidosis; titrate based on target serum bicarbonate; a range of ~2 to 10 mEq bicarbonate/kg/<b>day</b> has been reported, although some patients may require higher daily doses with close monitoring (ERKNet/ESPN [Trepiccione 2021]; Lopez-Garcia 2019; Rodríguez Soriano 2002; Santos 1986).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral: Initial: 2 to 4 mEq bicarbonate/kg/<b>day</b> in 3 to 4 divided doses. Younger patients (ie, &lt;6 years of age) may require higher doses to achieve targets (eg, up to 10 mEq bicarbonate/kg/<b>day</b>) (ERKNet/ESPN [Trepiccione 2021]; Giglio 2021; Lopez-Garcia 2019; Rodríguez Soriano 2002; Santos 1986; Soleimani 2016).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="22e8cf10-7078-43fd-ab81-1a8a524d3f14">Systemic alkalinization; chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Systemic alkalinization; chronic:</b> Limited data available: Infants, Children, and Adolescents: Oral: 2 to 3 mEq bicarbonate/kg/<b>day</b> in 3 to 4 divided doses; adjust dose to targeted serum bicarbonate levels; typical adult doses do not exceed 60 mEq/dose (Gal 2007).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="81636f70-534a-4834-ab07-6cae948fce1e">Urine alkalinization, urolithiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urine alkalinization, urolithiasis (cystinuria, uricosuria, hypocitraturia): </b></p>
<p style="text-indent:-2em;margin-left:4em;">Fixed dosing: Children and Adolescents: Oral: 10 to 30 mEq bicarbonate/dose after meals and at bedtime; typical adult doses do not exceed 60 mEq bicarbonate/dose (manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">Weight-directed dosing: Limited data available: Infants, Children, and Adolescents: Oral: Reported range: 0.5 to 4 mEq bicarbonate/kg/<b>day</b> in 4 divided doses; titrate to target pH (dependent on stone composition) (Copelovitch 2012; Elder 2020; Penido 2015; Santos-Victoriano 1998). Per the manufacturer, in adults, when used for urine alkalinization, doses of 20 to 30 mEq bicarbonate administered 4 times daily typically maintain urinary pH 7 to 7.6.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51154207"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling. Use is contraindicated in patients with anuria or severe renal impairment with oliguria or azotemia.</p></div>
<div class="block dohp drugH1Div" id="F51154208"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F53808906"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">See Potassium Citrate monograph.</p></div>
<div class="block coi drugH1Div" id="F212987"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to any ingredient of the formulation, severe renal insufficiency with oliguria or azotemia; untreated Addison disease; adynamia episodica hereditaria; acute dehydration; heat cramps; anuria; severe myocardial damage; hyperkalemia.</p></div>
<div class="block war drugH1Div" id="F212972"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• GI effects: May cause GI upset (eg, nausea, vomiting, diarrhea, abdominal pain, discomfort) and lead to GI ulceration, bleeding, perforation and/or obstruction requiring surgical intervention. Some fatal cases have been reported. Discontinue immediately if abdominal pain, distension, nausea, vomiting or GI bleeding occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperkalemia: Close monitoring of serum potassium concentrations is needed to avoid hyperkalemia; severe hyperkalemia may lead to muscle weakness/paralysis and cardiac conduction abnormalities (eg, heart block, ventricular arrhythmias, asystole).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acid/base disorders: Use with caution in patients with acid/base alterations; changes in serum potassium concentrations can occur during acid/base correction, monitor closely.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, heart failure, cardiac arrhythmias); patients may be more susceptible to life-threatening cardiac effects associated with hyper/hypokalemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Citrate is converted to bicarbonate in the liver; this conversion may be impaired in patients in hepatic failure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Potassium-altering conditions/disorders: Use with caution in patients with disorders or conditions likely to contribute to altered serum potassium and hyperkalemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; monitor serum potassium concentrations closely. Contraindicated in severe renal impairment with oliguria or azotemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Severely ill: Citrate is converted to bicarbonate in the liver; this conversion may be impaired in patients who are severely ill or in shock.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP ["Inactive" 1997]; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Dilute with water to minimize GI injury; administer after meals to minimize saline laxative effect.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878601"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block dosfc drugH1Div" id="F52027554"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Powder: Each packet contains 30 mEq potassium and delivers equivalent of 30 mEq of bicarbonate.</p>
<p style="text-indent:-2em;margin-left:2em;">Solution: Each 5 mL contains 10 mEq potassium and delivers equivalent of 10 mEq bicarbonate.</p></div>
<div class="block foc drugH1Div" id="F212981"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;">Powder for solution, oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Cytra-K: Potassium citrate monohydrate 3300 mg and citric acid monohydrate 1002 mg per packet (100s) [sugar free; fruit-punch flavor; each packet contains potassium 30 mEq equivalent to bicarbonate 30 mEq]</p>
<p style="text-indent:-2em;margin-left:2em;">Solution, oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Cytra-K: Potassium citrate monohydrate 1100 mg and citric acid monohydrate 334 mg per 5 mL (480 mL) [ethanol free, sugar free; contains propylene glycol; cherry flavor; contains potassium 2 mEq/mL equivalent to bicarbonate 2 mEq /mL]</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: Potassium citrate monohydrate 1100 mg and citric acid monohydrate 334 mg per 5 mL (473 mL)</p></div>
<div class="block geq drugH1Div" id="F212969"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F212988"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Potassium Citrate-Citric Acid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1100-334 mg/5 mL (per mL): $0.11 - $0.76</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F212984"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer after meals (to avoid laxative effect) and at bedtime. Administer additional water or juice after the dose, if needed.</p></div>
<div class="block admp drugH1Div" id="F52613654"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Dose should be diluted prior to administration to minimize injury due to high concentration of potassium; administer after meals and at bedtime to prevent saline laxative effect; may follow dose with additional water if necessary; dose may be chilled to improve palatability. </p></div>
<div class="block use drugH1Div" id="F212983"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Gout (adjuvant):</b> As an adjuvant to uricosurics in gout therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal tubular acidosis:</b> Treatment of acidosis in certain renal tubular disorders.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Urine alkalinizer:</b> Alkalinizing agent in conditions where long-term maintenance of alkaline urine is desirable.</p></div>
<div class="block mst drugH1Div" id="F27867370"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Polycitra may be confused with Bicitra</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299920"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F212976"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: Potassium Salts may enhance the hyperkalemic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists (Indirect-Acting): Alkalinizing Agents may increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aluminum Hydroxide: Citric Acid Derivatives may increase the absorption of Aluminum Hydroxide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: Alkalinizing Agents may increase the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AMILoride: Potassium Salts may enhance the hyperkalemic effect of AMILoride.  Management: Amiloride and potassium supplements should not be used except in severe or refractory cases of hypokalemia. If coadministered, monitor serum potassium closely as rapid increases in potassium are possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: Alkalinizing Agents may decrease the excretion of Amphetamines.  Management: Consider alternatives to using amphetamines and alkalinizing agents in combination. If these agents must be used together, patients should be monitored closely for excessive amphetamine effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Potassium Salts may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the ulcerogenic effect of Potassium Citrate. Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone-Containing Products: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension. Potassium supplements may be needed to treat/prevent hypokalemia in select patients with heart failure receiving eplerenone and high dose loop diuretics.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: Potassium Salts may enhance the hyperkalemic effect of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flecainide: Alkalinizing Agents may decrease the excretion of Flecainide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Alkalinizing Agents may increase the serum concentration of Mecamylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Memantine: Alkalinizing Agents may increase the serum concentration of Memantine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: Alkalinizing Agents may increase the serum concentration of QuiNINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: Potassium Salts may enhance the hyperkalemic effect of Spironolactone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triamterene: Potassium Salts may enhance the hyperkalemic effect of Triamterene. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F14287310"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Refer to potassium citrate monograph for information.</p></div>
<div class="block brc drugH1Div" id="F14287311"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Refer to potassium citrate monograph for information.</p></div>
<div class="block dic drugH1Div" id="F44661475"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take after meals to minimize laxative effect.</p></div>
<div class="block mop drugH1Div" id="F13203099"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum creatinine, BUN, LFTs, serum potassium, serum bicarbonate, urinary pH.</p></div>
<div class="block rer drugH1Div" id="F13203118"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Reference ranges may vary depending on the laboratory</p>
<p style="text-indent:-2em;margin-left:2em;">Urinary pH: 4.6-8.0</p></div>
<div class="block phk drugH1Div" id="F212986"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: ≥95% via hepatic oxidation to bicarbonate; may be impaired in patients with hepatic failure, in shock, or who are severely ill; citric acid is metabolized to CO<sub>2</sub> and H<sub>2</sub>O</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (&lt; 5% unchanged)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F14190110"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Alkamax | Alkurin | Citra k | Ck | Potacit | Ural k | Urikal | Urinor | Uriset | Urodel k | Urokool</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Litothone</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Uroclasio nf | Zurolix</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Mist.possit</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Jawalk | New age mist pot citrate | Panpek mist pot cit b.p.c</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Virtrate K</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Litrix</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31745987">
<a name="31745987"></a>Bjurulf B, Magnus P, Hallböök T, Strømme P. Potassium citrate and metabolic acidosis in children with epilepsy on the ketogenic diet: a prospective controlled study. <i>Dev Med Child Neurol</i>. 2020;62(1):57-61. doi:10.1111/dmcn.14393<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-drug-information/abstract-text/31745987/pubmed" id="31745987" target="_blank">31745987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22857835">
<a name="22857835"></a>Copelovitch, L. Urolithiasis in children: medical approach. <i>Pediatr Clin North Am</i>. 2012;59(4):881-896.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-drug-information/abstract-text/22857835/pubmed" id="22857835" target="_blank">22857835</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Cytra-K Crystals granule for solution (potassium citrate and citric acid) [prescribing information]. Morristown, NJ: Cypress Pharmaceutical Inc; September 2016.</div>
</li>
<li>
<div class="reference">
                  Cytra-K oral solution (potassium citrate and citric acid) [prescribing information]. Madison, MS: Cypress Pharmaceutical Inc; December 2011.</div>
</li>
<li>
<div class="reference">
                  Eichenwald EC. <i>Manual of Neonatal Care</i>. 8th edition. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference">
                  Elder JS. Urinary lithiasis. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020:chap. 562.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gal.2007">
<a name="Gal.2007"></a>Gal P, Reed M. Medications. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007: 2955-2999.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33770395">
<a name="33770395"></a>Giglio S, Montini G, Trepiccione F, Gambaro G, Emma F. Distal renal tubular acidosis: a systematic approach from diagnosis to treatment. <i>J Nephrol</i>. 2021;34(6):2073-2083. doi:10.1007/s40620-021-01032-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-drug-information/abstract-text/33770395/pubmed" id="33770395" target="_blank">33770395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29881797">
<a name="29881797"></a>Kossoff EH, Zupec-Kania BA, Auvin S, et al. Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group. <i>Epilepsia Open</i>. 2018;3(2):175-192. doi:10.1002/epi4.12225<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-drug-information/abstract-text/29881797/pubmed" id="29881797" target="_blank">29881797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30773598">
<a name="30773598"></a>Lopez-Garcia SC, Emma F, Walsh SB, et al. Treatment and long-term outcome in primary distal renal tubular acidosis. <i>Nephrol Dial Transplant</i>. 2019;34(6):981-991. doi:10.1093/ndt/gfy409<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-drug-information/abstract-text/30773598/pubmed" id="30773598" target="_blank">30773598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19596731">
<a name="19596731"></a>McNally MA, Pyzik PL, Rubenstein JE, Hamdy RF, Kossoff EH. Empiric use of potassium citrate reduces kidney-stone incidence with the ketogenic diet. <i>Pediatrics</i>. 2009;124(2):e300-e304. doi:10.1542/peds.2009-0217<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-drug-information/abstract-text/19596731/pubmed" id="19596731" target="_blank">19596731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26380196">
<a name="26380196"></a>Penido MG, Tavares Mde S. Pediatric primary urolithiasis: symptoms, medical management and prevention strategies. <i>World J Nephrol</i>. 2015;4(4):444-454.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-drug-information/abstract-text/26380196/pubmed" id="26380196" target="_blank">26380196</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Potassium citrate and citric acid solution [prescribing information]. Greenville, SC: Pharmaceutical Associates, Inc; March 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12138150">
<a name="12138150"></a>Rodríguez Soriano J. Renal tubular acidosis: the clinical entity. <i>J Am Soc Nephrol</i>. 2002;13(8):2160-2170. doi:10.1097/01.asn.0000023430.92674.e5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-drug-information/abstract-text/12138150/pubmed" id="12138150" target="_blank">12138150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3777038">
<a name="3777038"></a>Santos F, Chan JC. Renal tubular acidosis in children. Diagnosis, treatment and prognosis. <i>Am J Nephrol</i>. 1986;6(4):289-295.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-drug-information/abstract-text/3777038/pubmed" id="3777038" target="_blank">3777038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9793728">
<a name="9793728"></a>Santos-Victoriano M, Brouhard BH, Cunningham RJ 3rd. Renal stone disease in children. <i>Clin Pediatr (Phila)</i>. 1998;37(10):583-599.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-drug-information/abstract-text/9793728/pubmed" id="9793728" target="_blank">9793728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27188519">
<a name="27188519"></a>Soleimani M, Rastegar A. Pathophysiology of renal tubular acidosis: core curriculum 2016. <i>Am J Kidney Dis</i>. 2016;68(3):488-498. doi:10.1053/j.ajkd.2016.03.422<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-drug-information/abstract-text/27188519/pubmed" id="27188519" target="_blank">27188519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33914889">
<a name="33914889"></a>Trepiccione F, Walsh SB, Ariceta G, et al. Distal renal tubular acidosis: ERKNet/ESPN clinical practice points. <i>Nephrol Dial Transplant</i>. 2021;36(9):1585-1596. doi:10.1093/ndt/gfab171<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-drug-information/abstract-text/33914889/pubmed" id="33914889" target="_blank">33914889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10066 Version 133.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
